MILWAUKEE, Oct. 16, 2019 /PRNewswire/ -- Ademi &
O'Reilly, LLP is investigating Achillion (NASDAQ:ACHN) for possible
breaches of fiduciary duty and other violations of the law in
connection with the sale of Achillion to Alexion.
Click here to learn how to join the action:
http://ademilaw.com/case/achillion-pharmaceuticals-inc or call
Guri Ademi toll-free at
866-264-3995. There is no cost or obligation to you.
Ademi & O'Reilly, LLP alleges Achillion's financial outlook
is improving and yet shareholders will receive only $6.30 per share, with the potential for
additional consideration in the form of non-tradeable contingent
value rights, which will be paid to Achillion shareholders if
certain clinical and regulatory milestones are achieved within
specified periods. These include $1.00 per share for the U.S. FDA approval of
danicopan and $1.00 per share for
ACH-5228 Phase 3 initiation. Alexion is acquiring Achillion at a
substantial discount. The merger agreement unreasonably limits
competing bids for Achillion by prohibiting solicitation of further
bids, and imposing a termination penalty if Achillion accepts a
superior bid. Achillion insiders will receive millions of dollars
as part of change of control arrangements. We are investigating on
the conduct of Jagged Peak's board of directors, and whether they
are (i) fulfilling their fiduciary duties to all shareholders, and
(ii) obtaining a fair and reasonable price for Achillion.
If you own common stock in Achillion and wish to obtain
additional information, please contact Guri
Ademi either at gademi@ademilaw.com or toll-free:
866-264-3995, or
http://ademilaw.com/case/achillion-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts,
mergers, and individual shareholder rights throughout the country.
For more information, please feel free to call us. Attorney
advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & O'Reilly, LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original
content:http://www.prnewswire.com/news-releases/shareholder-alert-ademi--oreilly-llp-investigates-whether-achillion-pharmaceuticals-inc-has-obtained-a-fair-price-in-its-sale-to-alexion-pharmaceuticals-inc-300939594.html
SOURCE Ademi & O'Reilly, LLP
